V590

DB16437

biotech investigational

Deskripsi

The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®A226818, L30573, L30578. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one doseL30583. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocolL30583. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 32566261
    Wolf J, Bruno S, Eichberg M, Jannat R, Rudo S, VanRheenen S, Coller BA: Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. NPJ Vaccines. 2020 Jun 15;5:51. doi: 10.1038/s41541-020-0204-7. eCollection 2020.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul